吉西他滨联合顺铂辅助化学药物治疗非小细胞肺癌临床研究  

Clinical Study of Gemcitabine Combined with Cisplatin as an Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

作　　者：苗军程 MIAO Juncheng(Jinxiang People's Hospital,Jining,Shandong,China 272200)

机构地区：[1]山东省济宁市金乡县人民医院,山东济宁272200

出　　处：《中国药业》2024年第S01期33-35,共3页China Pharmaceuticals

摘　　要：目的探讨吉西他滨联合顺铂辅助化学药物治疗(简称化疗)非小细胞肺癌患者的临床疗效和安全性。方法选取医院2019年10月至2023年10月收治的非小细胞肺癌患者231例,随机分为观察组(116例)和对照组(115例),分别给予吉西他滨联合顺铂化疗和单一顺铂化疗。结果观察组患者总有效率显著高于对照组(P<0.05),且不良反应发生率显著低于对照组(P<0.05)。治疗后,观察组患者免疫指标、凝血指标及CD_(4)^(+),CD_(3)^(+),CD_(4)^(+)/CD_(8)^(+)水平均显著优于对照组(P<0.05)。结论吉西他滨联合顺铂辅助化疗治疗非小细胞肺癌可有效提升临床疗效及安全性,显著改善患者的免疫功能及凝血功能,促进患者身体机能恢复。Objective To investigate the clinical efficacy and safety of gemcitabine combined with cisplatin as an adjuvant chemotherapy in the treatment of patients with non-small cell lung cancer.Methods A total of 231 patients with non-small cell lung cancer admitted to the hospital from October 2019 to October 2023 were randomly divided into the observation group(116 cases)and the control group(115 cases),the patients in the two groups were treated with gemcitabine combined with cisplatin chemotherapy and cisplatin monotherapy,respectively.Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05),and the incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).After treatment,the immune indicators,coagulation indicators,CD_(4)^(+),CD_(3)^(+),and CD_(4)^(+)/CD_(8)^(+)levels in the observation group were significantly better than those in the control group(P<0.05).Conclusion Gemcitabine combined with cisplatin as an adjuvant chemotherapy in the treatment of patients with non-small cell lung cancer can effectively improve clinical efficacy and safety,significantly improve the patients′immune and coagulation functions,and promote physical recovery.

关 键 词：吉西他滨 顺铂 非小细胞肺癌 辅助化学治疗 临床疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]